Prevention of Epstein-Barr Virus Reactivation With the ATG-based Haploidentical Protocol Combined With Rituximab in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT07693881 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

106

Enrollment

OTHER

Sponsor class

Conditions

EBV Infection After Allogenic HSCT

Interventions

DRUG: Rituximab (R)

Sponsor

Nanfang Hospital, Southern Medical University